What question did this study set out to answer?

To assess the protective efficacy of an FCV-VP1 mRNA vaccine against FCV challenge in cats.

March 26, 2026Open Access

Feline calicivirus VP1-based mRNA vaccine protects cats against FCV challenge

Key Result

An FCV-VP1 mRNA-LNP vaccine provided complete protection in cats against highly pathogenic feline calicivirus challenge by eliciting effective and durable neutralizing antibodies.

Key Points

To assess the protective efficacy of an FCV-VP1 mRNA vaccine against FCV challenge in cats.
Constructed an FCV-VP1 mRNA vaccine using a lipid nanoparticle (LNP) platform.
Evaluated vaccine-induced immune responses, particularly neutralizing antibodies.
Tested vaccine efficacy by subjecting vaccinated cats to a FCV challenge.
The vaccine elicited effective and durable neutralizing antibody responses.
Cats receiving the vaccine showed complete protection from highly pathogenic FCV.
Vaccination offered a novel strategy for preventing FCV infection in cats.

Structured PICO

Does an FCV-VP1 mRNA-LNP vaccine protect cats against highly pathogenic FCV challenge?

Population

Cats

Intervention

FCV-VP1 mRNA-LNP vaccine

Outcome

Protection against highly pathogenic FCV challenge and neutralizing antibody response

An FCV-VP1 mRNA-LNP vaccine offers a novel and effective strategy by providing complete protection against FCV infection in cats.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

• An FCV-VP1 mRNA-LNP vaccine was constructed, utilizing a non-viral platform that enhances safety and production flexibility. • The vaccine elicits effective and durable neutralizing antibodies response, protecting cats from highly pathogenic FCV challenge. • This mRNA vaccine provided complete protection in cats, offering a novel and effective strategy against FCV infection.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Zang et al. (Sun,) reported a other. An FCV-VP1 mRNA-LNP vaccine provided complete protection in cats against highly pathogenic feline calicivirus challenge by eliciting effective and durable neutralizing antibodies.

synapsesocial.com/papers/69c4cddcfdc3bde44891a9e2 https://doi.org/https://doi.org/10.1016/j.virs.2026.03.010

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Perguntar à IA

Bookmark

View Full Paper